Michael Pourdehnad, Senior Vice President, Head of Early Clinical Development, Hematology/Oncology & Cell Therapy at Bristol Myers Squibb, shared a post on LinkedIn:
“During this year’s American Association for Cancer Research Annual Meeting in San Diego, I had the pleasure of presenting at the Oncology Industry Partnering Event to showcase how Bristol Myers Squibb is transforming what’s possible for patients and caregivers who are waiting for new options. At BMS, we’re focused on pursuing high-impact medicines with a disease-focused strategy, designing studies for the highest probability of success and leveraging AI and technology to move with greater speed and urgency.
These Spotlight Sessions are a reminder that progress in oncology happens when everyone in the scientific ecosystem stays anchored to what patients need most: new, meaningful options.
Thanks to the Chairs: Christiana Bardon, William N. Hait and Michael A Caligiuri for organizing. Thanks to my peers for inspiring me and for all the people I met during the times for networking.
I’m heading to AACR26 ready to keep this momentum and see what we can all do to drive what’s next.”
You can also read:
Highlights from AACR 2026 Day 1
